BACKGROUND: The safety and efficacy of front-line nilotinib and dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed the adverse event rates, response rates, and survival rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had been treated with front-line nilotinib (n = 108) or dasatinib (n = 107). RESULTS: The overall median follow-up period was 49 months. At baseline, 6 dasatinib-treated patients (6%) had mild renal dysfunction and 13 (12%) had mild liver dysfunction. Also, 8 nilotinib-treated patients (7%) had mild renal dysfunction, 1 (1%) moderate renal dysfunction, and 9 (8%) mild liver dysfunction. No significant differences were found in the rate of complete cytogenetic response, major molecular response, or molecular response by a 4.5 log reduction on the international scale between the organ function cohorts. Dasatinib- or nilotinib-treated patients with baseline renal dysfunction had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001), and nilotinib-treated patients with renal dysfunction had a greater incidence of bleeding (P < .001). CONCLUSION: Patients with CML-CP and mild to moderate renal or liver dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction.
BACKGROUND: The safety and efficacy of front-line nilotinib and dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed the adverse event rates, response rates, and survival rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had been treated with front-line nilotinib (n = 108) or dasatinib (n = 107). RESULTS: The overall median follow-up period was 49 months. At baseline, 6 dasatinib-treated patients (6%) had mild renal dysfunction and 13 (12%) had mild liver dysfunction. Also, 8 nilotinib-treated patients (7%) had mild renal dysfunction, 1 (1%) moderate renal dysfunction, and 9 (8%) mild liver dysfunction. No significant differences were found in the rate of complete cytogenetic response, major molecular response, or molecular response by a 4.5 log reduction on the international scale between the organ function cohorts. Dasatinib- or nilotinib-treated patients with baseline renal dysfunction had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001), and nilotinib-treated patients with renal dysfunction had a greater incidence of bleeding (P < .001). CONCLUSION: Patients with CML-CP and mild to moderate renal or liver dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction.
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra Journal: N Engl J Med Date: 2002-02-28 Impact factor: 91.245
Authors: J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes Journal: Blood Date: 1984-04 Impact factor: 22.113
Authors: Lisa J Christopher; Donghui Cui; Chiyuan Wu; Roger Luo; James A Manning; Samuel J Bonacorsi; Michael Lago; Alban Allentoff; Francis Y F Lee; Betty McCann; Susan Galbraith; Donald P Reitberg; Kan He; Anthony Barros; Anne Blackwood-Chirchir; W Griffith Humphreys; Ramaswamy A Iyer Journal: Drug Metab Dispos Date: 2008-04-17 Impact factor: 3.922
Authors: Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin Journal: Cancer Cell Date: 2005-02 Impact factor: 31.743
Authors: Mirna Golemovic; Srdan Verstovsek; Francis Giles; Jorge Cortes; Taghi Manshouri; Paul W Manley; Jürgen Mestan; Margaret Dugan; Leila Alland; James D Griffin; Ralph B Arlinghaus; Tong Sun; Hagop Kantarjian; Miloslav Beran Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: Ahmad Adel; Dina Abushanab; Anas Hamad; Mohammad Abdulla; Mohamed Izham; Mohamed Yassin Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302
Authors: Hassan Reda Hassan Elsayed; Randa El-Gamal; Mohammed R Rabei; Mona G Elhadidy; Shereen Hamed; Basma H Othman; Mohamed Mahmoud Abdelraheem Elshaer; Mostafa Khaled Sedky; Ahmed Tarek Abd Elbaset Hassan; Mohammad El-Nablaway Journal: Cells Date: 2022-02-21 Impact factor: 6.600
Authors: Dustyn A Barnette; Mary A Schleiff; Laura R Osborn; Noah Flynn; Matthew Matlock; S Joshua Swamidass; Grover P Miller Journal: Toxicology Date: 2020-05-11 Impact factor: 4.221